ICU Medical Beats Q2 Estimates, Raises 2026 EPS Guidance by 11%
ICUI sits 63% above its 52-week low of $107.
Summary
ICU Medical delivered a strong Q2, with revenue of $551.68M beating the $533.43M consensus and adjusted EPS of $2.37 crushing the $1.91 estimate. Infusion Systems drove the beat, while gross margin jumped to 43% from 38% a year ago. Management raised full-year 2026 adjusted EPS guidance to $8.60-$9.00, up from $7.75-$8.45, and GAAP EPS to $2.89-$3.29 from $1.03-$1.74. The stock is trading near its 52-week high, and this report reinforces the upward momentum. The divestiture of the IV Solutions business in May 2025 continues to affect Vital Care comparisons, but the core infusion business is accelerating.
At the time of this announcement, ICUI was trading at $174.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $107.00 to $176.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.